Pfizer Terminates Phase 1 Trial of Novel Anti-PD-1/IL-15 Fusion Protein in Solid Tumors
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
Summary
Pfizer conducted a Phase 1 trial testing PF-07209960, an experimental cancer immunotherapy that combines two immune-boosting mechanisms: blocking PD-1 (a checkpoint that cancer uses to hide from the immune system) and delivering IL-15 (a molecule that activates cancer-fighting immune cells). The study enrolled 37 patients with advanced non-small-cell lung cancer, head and neck squamous cell carcinoma, or renal cell carcinoma who had no remaining standard treatment options. The trial was designed in two parts — dose escalation to find a safe dose, followed by expansion in specific tumor types — but was ultimately terminated before completion. The early termination limits conclusions about the drug's safety profile and clinical benefit. This approach of fusing checkpoint inhibitors with immune-activating cytokines represents an active area of oncology research.
Detailed Summary
Combining immune checkpoint blockade with cytokine signaling represents one of the most promising frontiers in cancer immunotherapy. PF-07209960 was designed to exploit both pathways simultaneously — blocking PD-1 to unmask tumors from immune surveillance while delivering IL-15 to amplify the activity of T cells and natural killer cells. This dual mechanism was hypothesized to produce synergistic anti-tumor effects beyond what either approach achieves alone.
Pfizer initiated this first-in-human Phase 1 open-label, multicenter study in December 2020. The trial enrolled 37 participants with locally advanced or metastatic solid tumors — specifically non-small-cell lung cancer, head and neck squamous cell carcinoma, and renal cell carcinoma — for whom standard therapies were unavailable, inappropriate, or refused. The study was structured in two sequential parts: a dose escalation phase to identify a recommended dose, followed by a tumor-specific expansion phase.
The trial was terminated in May 2023, before the planned dose expansion phase could be fully executed. No efficacy or detailed safety results are publicly available from the abstract alone, leaving the clinical benefit and tolerability profile of PF-07209960 largely uncharacterized in the public domain.
The early termination is clinically significant. Phase 1 terminations in oncology can occur for multiple reasons including safety signals, lack of pharmacodynamic activity, strategic portfolio decisions, or competitive landscape changes. Without published results, it is impossible to determine which factor drove this decision.
For clinicians and researchers, this trial reflects the broader challenge of translating dual-mechanism immunotherapy constructs from preclinical promise to clinical success. The anti-PD-1/IL-15 fusion protein concept remains of scientific interest, and data from this terminated trial, if published, could inform next-generation designs in the field.
Key Findings
- PF-07209960 combines PD-1 checkpoint blockade with IL-15 cytokine activity in a single fusion protein.
- 37 patients with advanced NSCLC, head and neck, or renal cell carcinoma were enrolled before termination.
- Trial was terminated in May 2023 before completing the planned dose expansion phase.
- No efficacy or detailed safety data are publicly available from this terminated Phase 1 study.
- Dual anti-PD-1/IL-15 fusion proteins remain an active area of next-generation immunotherapy research.
Methodology
This was a first-in-human, open-label, multicenter Phase 1 dose escalation and expansion study sponsored by Pfizer. The two-part design aimed to establish a recommended dose in Part 1 before expanding into selected tumor types in Part 2. The trial enrolled patients with advanced solid tumors who lacked viable standard treatment options.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study data are not publicly available. The trial was terminated before completion, meaning no efficacy conclusions can be drawn and the full safety profile is unknown. The reasons for termination are not disclosed in the available public record.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.